High-dose therapy with iodine-131-labeled monoclonal antibody CC49 in patients with gastrointestinal cancers: A phase I trial

M. Tempero, P. Leichner, G. Dalrymple, K. Harrison, Samuel C. Augustine, J. Schlam, J. Anderson, J. Wisecarver, D. Colcher

Research output: Contribution to journalArticle

68 Citations (Scopus)

Abstract

Purpose: A phase I trial that evaluated far extrahematopoietic toxicity was conducted with iodine- 131 (131I) labeled monoclonal antibody (MAb) CC49. Correlative studies included pharmacokinetic and biodistribution analyses, estimates of absorbed radiation dose, and measurement of human antimonoclonal antibodies (HAMA). Patients and Methods: After collection and cryopreservation of hematopoietic stem cells, 15 patients with gastrointestinal cancers were administered a tracer dose of 131I-MAb CC49. Within 5 to 6 days, 14 patients (two to three per activity level) underwent a single treatment with 131I-MAb CC49 (50, 100, 150, 200, 250, and 300 mCi/m2). Biodistribution was determined using planar and single photon emission computer tomographic (SPECT) imaging. Pharmacokinetic studies were performed by measuring radioactivity in serial blood samples. In some patients, biopsies of metastases and related normal tissues were obtained for radioactivity measurements. Radiation dosimetry/estimates were calculated using available biodistribution, pharmacokinetic, and tissue biopsy data. Toxicity was evaluated using the National Cancer Institute (NCI) Common Toxicity Criteria. Results: No dose-limiting extrahematopoietic toxicity was identified. Twelve patients experienced grade IV myelosuppression and met criteria for infusion of hematopoietic stem cells. Radioimmunolocalization was excellent. The T(1/2) for 131I-MAb CC49 after diagnostic and therapeutic administration was 39.7 ± 10.4 and 46.1 ± 10.6 hours, respectively. The percent injected dose per killigram of tumor ranged from 0.2 to 2.1. Absorbed radiation dose in metastatic tumor sites ranged from 630 to 3300 cGy. Conclusion: Although extrahematopoietic dose-limiting toxicity was neither observed or predicted, suboptimal absorbed dose estimates suggested that further escalation of 131I-MAb CC49 would not be useful. Future studies should focus on the use of radionuclides with high energy β emissions, such as yttrium90, and on strategies to optimize access of antibody to target antigens.

Original languageEnglish
Pages (from-to)1518-1528
Number of pages11
JournalJournal of Clinical Oncology
Volume15
Issue number4
StatePublished - Apr 1997
Externally publishedYes

Fingerprint

Gastrointestinal Neoplasms
Iodine
Monoclonal Antibodies
Pharmacokinetics
Hematopoietic Stem Cells
Radioactivity
Radiation
Radiometry
Biopsy
Therapeutics
National Cancer Institute (U.S.)
Antibodies
Cryopreservation
Photons
Radioisotopes
Neoplasms
Neoplasm Metastasis
Antigens

All Science Journal Classification (ASJC) codes

  • Cancer Research
  • Oncology

Cite this

Tempero, M., Leichner, P., Dalrymple, G., Harrison, K., Augustine, S. C., Schlam, J., ... Colcher, D. (1997). High-dose therapy with iodine-131-labeled monoclonal antibody CC49 in patients with gastrointestinal cancers: A phase I trial. Journal of Clinical Oncology, 15(4), 1518-1528.

High-dose therapy with iodine-131-labeled monoclonal antibody CC49 in patients with gastrointestinal cancers : A phase I trial. / Tempero, M.; Leichner, P.; Dalrymple, G.; Harrison, K.; Augustine, Samuel C.; Schlam, J.; Anderson, J.; Wisecarver, J.; Colcher, D.

In: Journal of Clinical Oncology, Vol. 15, No. 4, 04.1997, p. 1518-1528.

Research output: Contribution to journalArticle

Tempero, M, Leichner, P, Dalrymple, G, Harrison, K, Augustine, SC, Schlam, J, Anderson, J, Wisecarver, J & Colcher, D 1997, 'High-dose therapy with iodine-131-labeled monoclonal antibody CC49 in patients with gastrointestinal cancers: A phase I trial', Journal of Clinical Oncology, vol. 15, no. 4, pp. 1518-1528.
Tempero, M. ; Leichner, P. ; Dalrymple, G. ; Harrison, K. ; Augustine, Samuel C. ; Schlam, J. ; Anderson, J. ; Wisecarver, J. ; Colcher, D. / High-dose therapy with iodine-131-labeled monoclonal antibody CC49 in patients with gastrointestinal cancers : A phase I trial. In: Journal of Clinical Oncology. 1997 ; Vol. 15, No. 4. pp. 1518-1528.
@article{0f0c945126fc4b44a5a5df18e178f636,
title = "High-dose therapy with iodine-131-labeled monoclonal antibody CC49 in patients with gastrointestinal cancers: A phase I trial",
abstract = "Purpose: A phase I trial that evaluated far extrahematopoietic toxicity was conducted with iodine- 131 (131I) labeled monoclonal antibody (MAb) CC49. Correlative studies included pharmacokinetic and biodistribution analyses, estimates of absorbed radiation dose, and measurement of human antimonoclonal antibodies (HAMA). Patients and Methods: After collection and cryopreservation of hematopoietic stem cells, 15 patients with gastrointestinal cancers were administered a tracer dose of 131I-MAb CC49. Within 5 to 6 days, 14 patients (two to three per activity level) underwent a single treatment with 131I-MAb CC49 (50, 100, 150, 200, 250, and 300 mCi/m2). Biodistribution was determined using planar and single photon emission computer tomographic (SPECT) imaging. Pharmacokinetic studies were performed by measuring radioactivity in serial blood samples. In some patients, biopsies of metastases and related normal tissues were obtained for radioactivity measurements. Radiation dosimetry/estimates were calculated using available biodistribution, pharmacokinetic, and tissue biopsy data. Toxicity was evaluated using the National Cancer Institute (NCI) Common Toxicity Criteria. Results: No dose-limiting extrahematopoietic toxicity was identified. Twelve patients experienced grade IV myelosuppression and met criteria for infusion of hematopoietic stem cells. Radioimmunolocalization was excellent. The T(1/2) for 131I-MAb CC49 after diagnostic and therapeutic administration was 39.7 ± 10.4 and 46.1 ± 10.6 hours, respectively. The percent injected dose per killigram of tumor ranged from 0.2 to 2.1. Absorbed radiation dose in metastatic tumor sites ranged from 630 to 3300 cGy. Conclusion: Although extrahematopoietic dose-limiting toxicity was neither observed or predicted, suboptimal absorbed dose estimates suggested that further escalation of 131I-MAb CC49 would not be useful. Future studies should focus on the use of radionuclides with high energy β emissions, such as yttrium90, and on strategies to optimize access of antibody to target antigens.",
author = "M. Tempero and P. Leichner and G. Dalrymple and K. Harrison and Augustine, {Samuel C.} and J. Schlam and J. Anderson and J. Wisecarver and D. Colcher",
year = "1997",
month = "4",
language = "English",
volume = "15",
pages = "1518--1528",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "4",

}

TY - JOUR

T1 - High-dose therapy with iodine-131-labeled monoclonal antibody CC49 in patients with gastrointestinal cancers

T2 - A phase I trial

AU - Tempero, M.

AU - Leichner, P.

AU - Dalrymple, G.

AU - Harrison, K.

AU - Augustine, Samuel C.

AU - Schlam, J.

AU - Anderson, J.

AU - Wisecarver, J.

AU - Colcher, D.

PY - 1997/4

Y1 - 1997/4

N2 - Purpose: A phase I trial that evaluated far extrahematopoietic toxicity was conducted with iodine- 131 (131I) labeled monoclonal antibody (MAb) CC49. Correlative studies included pharmacokinetic and biodistribution analyses, estimates of absorbed radiation dose, and measurement of human antimonoclonal antibodies (HAMA). Patients and Methods: After collection and cryopreservation of hematopoietic stem cells, 15 patients with gastrointestinal cancers were administered a tracer dose of 131I-MAb CC49. Within 5 to 6 days, 14 patients (two to three per activity level) underwent a single treatment with 131I-MAb CC49 (50, 100, 150, 200, 250, and 300 mCi/m2). Biodistribution was determined using planar and single photon emission computer tomographic (SPECT) imaging. Pharmacokinetic studies were performed by measuring radioactivity in serial blood samples. In some patients, biopsies of metastases and related normal tissues were obtained for radioactivity measurements. Radiation dosimetry/estimates were calculated using available biodistribution, pharmacokinetic, and tissue biopsy data. Toxicity was evaluated using the National Cancer Institute (NCI) Common Toxicity Criteria. Results: No dose-limiting extrahematopoietic toxicity was identified. Twelve patients experienced grade IV myelosuppression and met criteria for infusion of hematopoietic stem cells. Radioimmunolocalization was excellent. The T(1/2) for 131I-MAb CC49 after diagnostic and therapeutic administration was 39.7 ± 10.4 and 46.1 ± 10.6 hours, respectively. The percent injected dose per killigram of tumor ranged from 0.2 to 2.1. Absorbed radiation dose in metastatic tumor sites ranged from 630 to 3300 cGy. Conclusion: Although extrahematopoietic dose-limiting toxicity was neither observed or predicted, suboptimal absorbed dose estimates suggested that further escalation of 131I-MAb CC49 would not be useful. Future studies should focus on the use of radionuclides with high energy β emissions, such as yttrium90, and on strategies to optimize access of antibody to target antigens.

AB - Purpose: A phase I trial that evaluated far extrahematopoietic toxicity was conducted with iodine- 131 (131I) labeled monoclonal antibody (MAb) CC49. Correlative studies included pharmacokinetic and biodistribution analyses, estimates of absorbed radiation dose, and measurement of human antimonoclonal antibodies (HAMA). Patients and Methods: After collection and cryopreservation of hematopoietic stem cells, 15 patients with gastrointestinal cancers were administered a tracer dose of 131I-MAb CC49. Within 5 to 6 days, 14 patients (two to three per activity level) underwent a single treatment with 131I-MAb CC49 (50, 100, 150, 200, 250, and 300 mCi/m2). Biodistribution was determined using planar and single photon emission computer tomographic (SPECT) imaging. Pharmacokinetic studies were performed by measuring radioactivity in serial blood samples. In some patients, biopsies of metastases and related normal tissues were obtained for radioactivity measurements. Radiation dosimetry/estimates were calculated using available biodistribution, pharmacokinetic, and tissue biopsy data. Toxicity was evaluated using the National Cancer Institute (NCI) Common Toxicity Criteria. Results: No dose-limiting extrahematopoietic toxicity was identified. Twelve patients experienced grade IV myelosuppression and met criteria for infusion of hematopoietic stem cells. Radioimmunolocalization was excellent. The T(1/2) for 131I-MAb CC49 after diagnostic and therapeutic administration was 39.7 ± 10.4 and 46.1 ± 10.6 hours, respectively. The percent injected dose per killigram of tumor ranged from 0.2 to 2.1. Absorbed radiation dose in metastatic tumor sites ranged from 630 to 3300 cGy. Conclusion: Although extrahematopoietic dose-limiting toxicity was neither observed or predicted, suboptimal absorbed dose estimates suggested that further escalation of 131I-MAb CC49 would not be useful. Future studies should focus on the use of radionuclides with high energy β emissions, such as yttrium90, and on strategies to optimize access of antibody to target antigens.

UR - http://www.scopus.com/inward/record.url?scp=0030973970&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030973970&partnerID=8YFLogxK

M3 - Article

C2 - 9193348

AN - SCOPUS:0030973970

VL - 15

SP - 1518

EP - 1528

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 4

ER -